IPO Issue Details
Issue Price / Price Band₹593 per share (Fixed Price)
Face Value₹1 Per Share
Lot Size25 Shares per Lot
Total Issue Size1,50,92,750 shares (aggregating up to ₹895.00 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenFri, 21 Nov 2025
Subscription CloseTue, 25 Nov 2025
Anchor AllotmentThu, 20 Nov 2025
Basis of AllotmentWed, 26 Nov 2025
Initiation of RefundsThu, 27 Nov 2025
Credit of Shares to DematThu, 27 Nov 2025
Listing DateFri, 28 Nov 2025
UPI Mandate Deadline2025-11-25
Application & Investment Details
Retail — Min (1 Lots)₹14,825 — 25 shares
Retail — Max (13 Lots)₹192,725 (13 Lots)
HNI — Min (68 Lots)₹10,08,100 — 1,700 shares
EPS (Pre-IPO)₹12.46
EPS (Post-IPO)₹11.07
P/E Ratio (Pre-IPO)47.61x
P/E Ratio (Post-IPO)53.55x
Pre-IPO Promoter Holding11,13,46,602 shares
Post-IPO Promoter Holding11,29,48,626 shares
Fresh Issue Shares16,02,024 shares (aggregating up to ₹95.00 Cr)
Offer for Sale Shares1,34,90,726 shares of ₹1 (aggregating up to ₹800.00 Cr)
About Sudeep Pharma Ltd.
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectorsThe company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.Product Portfolio:Pharmaceutical, Food and Nutrition BusinessSpecialty Ingredients BusinessTrituratesAs of December 31, 2024, the company had 704 permanent employees.Competitve Strengths:Market leadership with a diversified product portfolio in a high barrier industryDistinguished global customer base with long-standing relationships with key customersWell-equipped and regulatory compliant Manufacturing FacilitiesStrong research and development capabilities
Objects of the Issue
Sudeep Pharma Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I
75.81
2
General corporate purposes
12.67
Shareholding & Lock-in
Pre-IPO Promoter Holding
11,13,46,602 shares
Post-IPO Promoter Holding
11,29,48,626 shares
Lock-in Period (30%)December 26, 2025
Lock-in Period (50%)February 24, 2026